Abstract
AimsThe delivery of radical radiotherapy in lung cancer is complicated by respiratory-induced tumour motion. The aim of the study was to correlate tumour motion characteristics with tumour and patient factors, particularly the anatomical lobe and pulmonary zone. Materials and methodsLung tumour volumes on four-dimensional computed tomography were delineated by a single observer at maximal expiration and propagated through all 10 phases of the breathing cycle. Movements were tracked in the superior–inferior (SI), anterior–posterior (AP) and medio-lateral (ML) directions by changes in the tumour centroid coordinates. Tumour motion characteristics were correlated with anatomical lobe, pulmonary zone, tumour volume, T-stage, smoking status and spirometry. ResultsIn 101 consecutive patients, the median magnitude of tumour motion in the SI direction was significantly larger in tumours located in lower lobes compared with upper lobes and middle/lingular lobes (0.70 cm versus 0.09 cm versus 0.26 cm, P < 0.01). No significant difference was found in median tumour motion between lower, upper and middle/lingular lobes in the AP (0.16 cm versus 0.13 cm versus 0.16 cm, P = 0.45) and ML (0.08 cm versus 0.08 cm versus 0.13 cm, P = 0.32) directions, respectively. When assessed by zone, the median tumour displacement in the SI direction was significantly larger in the lower zones (0.81 cm) as compared with the middle zones (0.30 cm) and upper zones (0.11 cm), P < 0.01. No difference was observed in the AP (P = 0.45) and ML (P = 0.73) directions. Tumour volume, T-stage and forced expiratory ratio were not statistically significant predictors of respiratory-induced tumour motion. ConclusionRespiratory-induced tumour motion in the SI direction was significantly greater in lower lobe and lower pulmonary zone tumours compared with apical tumours. Tumour volume, T-stage and spirometry did not correlate with the magnitude or direction of respiratory-induced tumour motion. During curative radiotherapy in lung cancer, attention should be paid to motion management, especially for lower lobe tumours.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.